These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 11491389

  • 1. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
    Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thompson PI, Baguley BC.
    Xenobiotica; 2001 May; 31(5):277-93. PubMed ID: 11491389
    [Abstract] [Full Text] [Related]

  • 2. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S, Kestell P, Baguley BC, Paxton JW.
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
    Zhou S, Paxton JW, Kestell P, Tingle MD.
    J Pharm Pharmacol; 2001 Apr; 53(4):463-71. PubMed ID: 11341362
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S, Paxton JW, Kestell P, Tingle MD, Ching LM.
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [Abstract] [Full Text] [Related]

  • 8. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
    Zhou S, Kestell P, Paxton JW.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep 05; 776(2):231-6. PubMed ID: 12138005
    [Abstract] [Full Text] [Related]

  • 9. High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zho S, Chiang D, Chin R, Kestell P, Paxton JW.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb 05; 767(1):19-26. PubMed ID: 11863291
    [Abstract] [Full Text] [Related]

  • 10. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S, Paxton JW, Tingle MD, Kestell P.
    Drug Metab Dispos; 2000 Dec 05; 28(12):1449-56. PubMed ID: 11095582
    [Abstract] [Full Text] [Related]

  • 11. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S, Kestell P, Tingle MD, Paxton JW.
    Cancer Chemother Pharmacol; 2002 Feb 05; 49(2):126-32. PubMed ID: 11862426
    [Abstract] [Full Text] [Related]

  • 12. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
    Zhou SF, Tingle MD, Kestell P, Paxton JW.
    Xenobiotica; 2002 Feb 05; 32(2):87-107. PubMed ID: 11868972
    [Abstract] [Full Text] [Related]

  • 13. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S, Kestell P, Baguley BC, Paxton JW.
    Biochem Pharmacol; 2003 Jun 01; 65(11):1853-65. PubMed ID: 12781337
    [Abstract] [Full Text] [Related]

  • 14. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching LM.
    Cancer Chemother Pharmacol; 2000 Jun 01; 46(2):135-41. PubMed ID: 10972483
    [Abstract] [Full Text] [Related]

  • 15. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L, Kestell P, Philpott M, Ching LM, Zhuang L, Baguley BC.
    Cancer Chemother Pharmacol; 2001 Jun 01; 47(6):491-7. PubMed ID: 11459201
    [Abstract] [Full Text] [Related]

  • 16. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L, Kestell P, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2002 Jan 01; 49(1):20-6. PubMed ID: 11855749
    [Abstract] [Full Text] [Related]

  • 17. Determinaton of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection.
    Zhou S, Paxton JW, Tingle MD, McCall J, Kestell P.
    J Chromatogr B Biomed Sci Appl; 1999 Oct 29; 734(1):129-36. PubMed ID: 10574198
    [Abstract] [Full Text] [Related]

  • 18. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
    Zhou S, Kestell P, Paxton JW.
    J Pharm Pharmacol; 2002 Jul 29; 54(7):997-1003. PubMed ID: 12162720
    [Abstract] [Full Text] [Related]

  • 19. 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3.
    Zhou S, Kestell P, Paxton JW.
    Eur J Drug Metab Pharmacokinet; 2002 Jul 29; 27(3):179-83. PubMed ID: 12365199
    [Abstract] [Full Text] [Related]

  • 20. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Zhou S, Kestell P, Tingle MD, Ching LM, Paxton JW.
    Cancer Chemother Pharmacol; 2001 Jun 29; 47(6):541-4. PubMed ID: 11459209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.